CRYSTALLINE FORM OF THE P38 KINASE INHIBITOR 2-{4 -[3-(4-CHLORO -2-FLUOROPHENYL) -4-PYRIMIDIN-4 -YL-LH-PYRAZOL -5-YL]PIPERIDIN -1-YL}-2 -OXOETHANOL

• Main Authors: RICHARD R. SCHARTMAN, DOUG H. HOFFMAN
• Format: Patent
• Language: English; Spanish
• Published: 19.12.2006
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Crystalline form of the p38 kinase inhibitor 2-{4-[3 -(4-chloro -2-fluorophenyl) -4-pyrimidin-4-yl -lH-pyrazol-5 -yl]piperidin -1-yl} -2-oxoethanol can be used, is provided. The crystalline form is a hydrated crystalline form. Also provided are combinations and pharmaceutical compositions comprising the crystalline form, process for preparing the crystalline form and for preparing compositions comprising the crystalline form, in methods for the prophylaxis and/or treatment of a p38 kinase-mediated condition comprising administering to a subject a therapeutically effective amount of the crystalline form of 1. Se proporciona una forma cristalina del inhibidor de la cinasa p38 2-{4- [3-(4-cloro-2 -fluorometil)-4- pirimidin-4-il -1H-pirazol-5-il] piperidin-1-il} -2-oxoetanol; la forma cristalina es una forma cristalina hidratada; tambien se proporcionan combinaciones y composiciones farmaceuticas que comprenden la forma cristalina, procedimientos para preparar la forma cristalina y para preparar composiciones que comprenden la forma cristalina, y metodos para la profilaxis y/o el tratamiento de una afeccion mediada por la cinasa p38 que comprende administrar a un sujeto una cantidad terapeuticamente eficaz de la forma cristalina.